BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel) 2020;12:E1275. [PMID: 32443546 DOI: 10.3390/cancers12051275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Mau Lo C, Man K. Role of Intrahepatic Regional Immunity in Post-Transplant Cancer Recurrence. Engineering 2021. [DOI: 10.1016/j.eng.2021.11.012] [Reference Citation Analysis]
2 Liu X, Zhang P, Song X, Cui H, Shen W. PPARγ Mediates Protective Effect against Hepatic Ischemia/Reperfusion Injury via NF-κB Pathway. J Invest Surg 2022;:1-12. [PMID: 35732295 DOI: 10.1080/08941939.2022.2090033] [Reference Citation Analysis]
3 Chen W, Huang L, Liang J, Ye Y, He S, Niu J. Hepatocellular carcinoma cells-derived exosomal microRNA-378b enhances hepatocellular carcinoma angiogenesis. Life Sci 2021;273:119184. [PMID: 33577844 DOI: 10.1016/j.lfs.2021.119184] [Reference Citation Analysis]
4 Jeong J, Tanaka M, Iwakiri Y. Hepatic lymphatic vascular system in health and disease. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.025] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Bhat M, Clotet-Freixas S, Baciu C, Pasini E, Hammad A, Ivanics T, Reid S, Azhie A, Angeli M, Ghanekar A, Fischer S, Sapisochin G, Konvalinka A. Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan. Clin Proteomics 2021;18:27. [PMID: 34794390 DOI: 10.1186/s12014-021-09333-x] [Reference Citation Analysis]
6 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Reference Citation Analysis]
7 Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Hobbs GS, Quaas A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, Duda DG. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer 2020;8:e001435. [PMID: 33234602 DOI: 10.1136/jitc-2020-001435] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]